Modern diagnosis of small cell malignancies of children

Surgical Pathology Clinics

Volumn 3, Issue 3, 2010, Pages 515-551

  Parham, David M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Diagnosis; Ewing sarcoma; Neuroblastoma; Pediatric neoplasia; Rhabdomyosarcoma; Small round blue cell tumors; Soft tissue sarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD99 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DESMIN; DOXORUBICIN; LACTATE DEHYDROGENASE; LEUKOSIALIN; MYOD PROTEIN; MYOGENIN; NEURON SPECIFIC ENOLASE; PROTEIN S 100; SYNAPTOPHYSIN; VINCRISTINE;

ADRENAL CORTEX CARCINOMA; AGE; ANEMIA; BIOLOGY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SIZE; CANCER STAGING; CARCINOID; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOLOGY; CYTOPLASM; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIFFERENTIAL DIAGNOSIS; DNA TRANSCRIPTION; ELECTRON MICROSCOPY; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; FEVER; FIBROMATOSIS; GENE DELETION; GENE FUSION; GERM CELL TUMOR; GRANULOCYTIC SARCOMA; HEPATOBLASTOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEIOMYOSARCOMA; LEUKEMIA; LIPOSARCOMA; LUNG BLASTOMA; LYMPHOMA; METASTASIS; NEPHROBLASTOMA; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NEUROECTODERM TUMOR; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RHABDOMYOMA; RHABDOMYOSARCOMA; ROSETTE FORMATION; SENSITIVITY AND SPECIFICITY; SMALL CELL CARCINOMA; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA; TUMOR DIFFERENTIATION;

EID: 77958140564     PISSN: 18759181     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.path.2010.06.002     Document Type: Review

References (76)

1. Carpentieri D.F., Qualman S.J., Bowen J., et al. Protocol for the examination of specimens from pediatric and adult patients with osseous and extraosseous Ewing sarcoma family of tumors, including peripheral primitive neuroectodermal tumor and Ewing sarcoma. Arch Pathol Lab Med 2005, 129:866-873.
2. Qualman S.J., Bowen J., Fitzgibbons P.L., et al. Protocol for the examination of specimens from patients with neuroblastoma and related neuroblastic tumors. Arch Pathol Lab Med 2005, 129:874-883.
3. Qualman S.J., Bowen J., Parham D.M., et al. Protocol for the examination of specimens from patients (children and young adults) with rhabdomyosarcoma. Arch Pathol Lab Med 2003, 127:1290-1297.
4. Qualman S.J., Bowen J., Amin M.B., et al. Protocol for the examination of specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood. Arch Pathol Lab Med 2003, 127:1280-1289.
5. Chiles M.C., Parham D.M., Qualman S.J., et al. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Pediatr Dev Pathol 2004, 7:583-594. [erratum appears in Pediatr Dev Pathol 2005;8(1):141].
6. Gaffney E.F., Dervan P.A., Fletcher C.D. Pleomorphic rhabdomyosarcoma in adulthood: analysis of 11 cases with definition of diagnostic criteria. Am J Surg Pathol 1993, 17:601-609.
7. Newton W.A., Gehan E.A., Webber B.L., et al. Classification of rhabdomyosarcoma and related sarcomas: pathologic aspects and proposal for a new classification-an Intergroup Rhabdomyosarcoma Study. Cancer 1995, 76:1073-1085.
8. Qualman S., Lynch J., Bridge J., et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Cancer 2008, 113:3242-3247.
9. Crist W.M., Anderson J.R., Meza J.L., et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001, 19:3091-3102.
10. Cessna M.H., Zhou H., Perkins S.L., et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. Am J Surg Pathol 2001, 25:1150-1157.
11. Folpe A.L. MyoD1 and myogenin expression in human neoplasia: a review and update [review]. Adv Anat Pathol 2002, 9:198-203.
12. Morotti R.A., Nicol K.K., Parham D.M., et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 2006, 30:962-968.
13. Wang N.P., Marx J., McNutt M.A., et al. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 1995, 147:1799-1810.
14. Pinto A., Tallini G., Novak R.W., et al. Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. Med Pediatr Oncol 1997, 28:165-170.
15. Miki H., Kobayashi S., Kushida Y., et al. A case of infantile rhabdomyofibrosarcoma with immunohistochemical, electronmicroscopical, and genetic analyses. Hum Pathol 1999, 30:1519-1522.
16. Cessna M.H., Zhou H., Sanger W.G., et al. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 2002, 15:931-938.
17. Bahrami A., Gown A.M., Baird G.S., et al. Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod Pathol 2008, 21:795-806.
18. Folpe A.L., Patterson K., Gown A.M. Antibodies to desmin identify the blastemal component of nephroblastoma. Mod Pathol 1997, 10:895-900.
19. Kodet R., Fajstavr J., Kabelka Z., et al. Is fetal cellular rhabdomyoma an entity or a differentiated rhabdomyosarcoma? A study of patients with rhabdomyoma of the tongue and sarcoma of the tongue enrolled in the intergroup rhabdomyosarcoma studies I, II, and III. Cancer 1991, 67:2907-2913.
20. Nucci M.R., Young R.H., Fletcher C.D. Cellular pseudosarcomatous fibroepithelial stromal polyps of the lower female genital tract: an underrecognized lesion often misdiagnosed as sarcoma. Am J Surg Pathol 2000, 24:231-240.
21. Meyer W.H., Spunt S.L. Soft tissue sarcomas of childhood. Cancer Treat Rev 2004, 30:269-280.
22. Lager J.J., Lyden E.R., Anderson J.R., et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006, 24:3415-3422.
23. Wharam M.D., Meza J., Anderson J., et al. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2004, 22:1902-1908.
24. Khoury J.D. Ewing sarcoma family of tumors [review]. Adv Anat Pathol 2005, 12:212-220.
25. Rud N.P., Reiman H.M., Pritchard D.J., et al. Extraosseous Ewing's sarcoma: a study of 42 cases. Cancer 1989, 64:1548-1553.
26. Jaffe R., Santamaria M., Yunis E.J., et al. The neuroectodermal tumor of bone. Am J Surg Pathol 1984, 8:885-898.
27. O'Sullivan M.J., Perlman E.J., Furman J., et al. Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study. Hum Pathol 2001, 32:1109-1115.
28. Mobley B.C., Roulston D., Shah G.V., et al. Peripheral primitive neuroectodermal tumor/Ewing's sarcoma of the craniospinal vault: case reports and review. Hum Pathol 2006, 37:845-853.
29. Chow E., Merchant T.E., Pappo A., et al. Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys 2000, 46:433-438.
30. Parham D.M., Hijazi Y., Steinberg S.M., et al. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol 1999, 30:911-918.
31. Renshaw A.A., Perezatayde A.R., Fletcher J.A., et al. Cytology of typical and atypical Ewings sarcoma PNET. Am J Clin Pathol 1996, 106:620-624.
32. Coffin C.M., Lowichik A., Zhou H., et al. Treatment effects in pediatric soft tissue and bone tumors: practical considerations for the pathologist [review]. Am J Clin Pathol 2005, 123:75-90.
33. Bacci G., Ferrari S., Bertoni F., et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000, 18:4-11.
34. Dehner L.P. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol 1993, 17:1-13.
35. Boue D.R., Parham D.M., Webber B., et al. Clinicopathologic study of ectomesenchymomas from Intergroup Rhabdomyosarcoma Study Groups III and IV. Pediatr Dev Pathol 2000, 3:290-300.
36. Sorensen P.H., Shimada H., Liu X.F., et al. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res 1995, 55:1385-1392.
37. Kleinschmidt-Demasters B.K., Lovell M.A., Donson A.M., et al. Molecular array analyses of 51 pediatric tumors shows overlap between malignant intracranial ectomesenchymoma and MPNST but not medulloblastoma or atypical teratoid rhabdoid tumor. Acta Neuropathol 2007, 113:695-703.
38. Folpe A.L., Goldblum J.R., Rubin B.P., et al. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol 2005, 29:1025-1033.
39. Folpe A.L., Hill C.E., Parham D.M., et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000, 24:1657-1662.
40. Ahmed A.A., Nava V.E., Pham T., et al. Ewing sarcoma family of tumors in unusual sites: confirmation by RT-PCR. Pediatr Dev Pathol 2006, 9:488-495.
41. Ellison D.A., Parham D.M., Bridge J., et al. Immunohistochemistry of primary malignant neuroepithelial tumors of the kidney: a potential source of confusion? A study of 30 cases from the National Wilms Tumor Study Pathology Center. Hum Pathol 2007, 38:205-211.
42. Katz R.L., Quezado M., Senderowicz A.M., et al. An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript. Hum Pathol 1997, 28:502-509.
43. Wang L., Bhargava R., Zheng T., et al. Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions. J Mol Diagn 2007, 9:498-509. [see comment].
44. Bridge R.S., Rajaram V., Dehner L.P., et al. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 2006, 19:1-8.
45. Ng T.L., O'Sullivan M.J., Pallen C.J., et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J Mol Diagn 2007, 9:459-463.
46. Wexler L.H., Delaney T.F., Tsokos M., et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 1996, 78:901-911.
47. Rodriguez-Galindo C., Liu T., Krasin M.J., et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007, 110:375-384.
48. Bacci G., Longhi A., Ferrari S., et al. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006, 45:469-475.
49. Schmidt D., Herrmann C., Jurgens H., et al. Malignant peripheral neuroectodermal tumor and its necessary distinction from Ewing's sarcoma. A report from the Kiel Pediatric Tumor Registry. Cancer 1991, 68:2251-2259.
50. Carvajal R., Meyers P., Carvajal R., et al. Ewing's sarcoma and primitive neuroectodermal family of tumors [review]. Hematol Oncol Clin North Am 2005, 19:501-525.
51. Bacci G., Ferrari S., Bertoni F., et al. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the Instituto Rizzoli. J Clin Oncol 2000, 18:885-892.
52. De Alava E., Panizo A., Antonescu C.R., et al. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000, 156:849-855.
53. Oberlin O., Rey A., Desfachelles A.S., et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol 2006, 24:3997-4002.
54. Kuttesch J.F., Parham D.M., Kaste S.C., et al. Embryonal malignancies of unknown primary origin in children. Cancer 1995, 75:115-121.
55. Dubois S.G., London W.B., Zhang Y., et al. Lung metastases in neuroblastoma at initial diagnosis: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2008, 51:589-592.
56. Shamberger R.C., Smith E.I., Joshi V.V., et al. The risk of nephrectomy during local control in abdominal neuroblastoma. J Pediatr Surg 1998, 33:161-164.
57. Shimada H., Ambros I.M., Dehner L.P., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999, 86:364-372.
58. Abramowsky C.R., Katzenstein H.M., Alvarado C.S., et al. Anaplastic large cell neuroblastoma. Pediatr Dev Pathol 2009, 12:1-5.
59. Min K.W. Usefulness of electron microscopy in the diagnosis of " small" round cell tumors of the sinonasal region. Ultrastruct Pathol 1995, 19:347-363.
60. Wick M.R. Immunohistology of neuroendocrine and neuroectodermal tumors. Semin Diagn Pathol 2000, 17:194-203.
61. Miettinen M., Chatten J., Paetau A., et al. Monoclonal antibody NB84 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 1998, 22:327-332.
62. Carter R.L., Al-Sam S.Z., Corbett R.P., et al. A comparative study of immunohistochemical staining for neuron-specific enolase, protein gene product 9.5 and S-100 protein in neuroblastoma, Ewing's sarcoma and other round cell tumours in children. Histopathology 1990, 16:461-467.
63. Campbell L.K., Thomas J.R., Lamps L.W., et al. Protein gene product 9.5 (PGP 9.5) is not a specific marker of neural and nerve sheath tumors: an immunohistochemical study of 95 mesenchymal neoplasms. Mod Pathol 2003, 16:963-969.
64. Trager C., Kogner P., Lindskog M., et al. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003, 49:104-112.
65. Robles-Frias M.J., Segura D.I., Marquez C., et al. Neuroblastoma initially presenting as a primary bone tumor: diagnostic value of molecular assays for tyrosine hydroxylase. Med Pediatr Oncol 2003, 40:167-170.
66. Wieneke J.A., Thompson L.D., Heffess C.S. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 2003, 27:867-881.
67. London W.B., Castleberry R.P., Matthay K.K., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005, 23:6459-6465.
68. Kushner B.H., Cheung N.K., LaQuaglia M.P., et al. International Neuroblastoma Staging System stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol 1996, 14:2174-2180.
69. Shimada H., Umehara S., Monobe Y., et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001, 92:2451-2461.
70. Bordow S.B., Norris M.D., Haber P.S., et al. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma [review]. J Clin Oncol 1998, 16:3286-3294.
71. Maris J.M., Matthay K.K. Molecular biology of neuroblastoma. J Clin Oncol 1999, 17:2264-2279.
72. Elimam N.A., Atra A.A., Fayea N.Y., et al. Stage 4S neuroblastoma, a disseminated tumor with excellent outcome. Saudi Med J 2006, 27:1734-1736.
73. Joshi V.V. Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of Shimada classification). Pediatr Dev Pathol 2000, 3:184-199.
74. Shimada H., Stram D.O., Chatten J., et al. Identification of subsets of neuroblastomas by combined histopathologic and n-myc analysis. J Natl Cancer Inst 1995, 87:1470-1476.
75. George R.E., Variend S., Cullinane C., et al. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol 2001, 36:169-176.
76. Mercado G.E., Xia S.J., Zhang C., et al. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 2008, 47:510-520.